Encapsulation characteristics of nystatin in liposomes: Effects of cholesterol and polyethylene glycol derivatives

International Journal of Pharmaceutics

Volumn 188, Issue 2, 1999, Pages 193-202

  Moribe, Kunikazu ^a   Maruyama, Kazuo ^a   Iwatsuru, Motoharu ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

31P NMR; Fluorescence; Liposome; Nystatin; Polyethylene glycol

Indexed keywords

AMPHOTERICIN B; CHOLESTEROL; DIPALMITOYLPHOSPHATIDYLCHOLINE; DISTEAROYL N [MONOETHOXY POLY(ETHYLENE GLYCOL)SUCCINYL]PHOSPHATIDYLETHANOLAMINE; LIPOSOME; MACROGOL; NYSTATIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG BINDING; DRUG STRUCTURE; ENCAPSULATION; FLUORESCENCE; LIPID COMPOSITION; MOLECULAR WEIGHT; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; CHOLESTEROL; DRUG COMPOUNDING; FLUORESCENCE; LIPOSOMES; MAGNETIC RESONANCE SPECTROSCOPY; NYSTATIN; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS;

EID: 0032824411     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(99)00222-7     Document Type: Article

References (19)

1. Coutinho A., Prieto M. Self-association of the polyene antibiotic nystatin in dipalmitoylphosphatidylcholine vesicles: a time-resolved fluorescence study. Biophys. J. 69:1995;2541-2557.
2. Gates G., Pinney R.J. Amphotericin B and its delivery by liposomal and lipid formulations. J. Clin. Phamacol. Ther. 18:1993;147-153.
3. Hiemenz J.W., Walsh T.J. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22(Suppl. 2):1996;S133-S144.
4. Janknegt R., De Marie S., Bakker-Woudenberg I.A.J.M., Crommelin D.J.A. Liposomal and lipid formulations of Amphotericin B - clinical pharmacokinetics. Clin. Pharmacokinet. 23:1992;279-291.
5. Maruyama K., Yuda T., Okamoto S., Kojima S., Suginaka A., Iwatsuru M. Prolonged circulation time in vitro of large unilamellar liposomes composed of distearoyl-phosphatidylcholine and cholesterol containing amphiphatic poly(ethylene glycol). Biochim. Biophys. Acta. 1128:1992;44-49.
6. Mechlinski W., Schaffner C.P. N-Acylation and esterification reactions with amphotericin B. J. Antibiot. 25:1972;256-258.
7. Mehta R.T., Hopfer R.L., Gunner L.A., Juliano R.L., LopezBerestein G. Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob. Agents Chemother. 31:1987;1897-1900.
8. Mehta R.T., Hopfer R.L., McQueen T., Juliano R.L., LopezBerestein G. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob. Agents Chemother. 31:1987;1901-1903.
9. Milhaud J., Berrehar J., Lancelin J.M., Michels B., Raffard G., Dufourc E.J. Association of polyene antibiotics with sterol-free lipid membranes II. Hydrophobic binding of nystatin to dilauroylphosphatidylcholine bilayers. Biochim. Biophys. Acta. 1326:1997;54-66.
10. Moribe K., Tanaka E., Maruyama K., Iwatsuru M. Enhanced encapsulation of amphotericin B into liposomes by complex formation with polyethylene glycol derivatives. Pharm. Res. 15:1998;1737-1742.
11. Newcomer V.D., Wright E.T., Sternberg T.H., Graham J.H., Wier R.H., Egeberg R.O. Evaluation of nystatin in the treatment of coccidioidomycosis in man. Sternberg T.H., Newcomer V.D. Therapy of Fungus Diseases. 1955;Little, Brown and Co, Boston, MA.
12. Oehling A., Giron M., Subira M.L. Aerosol chemotherapy in bronchopulmonary candidiasis. Respiration. 32:1975;179-184.
13. Otsubo T., Maruyama K., Maesaki S., Miyazaki Y., Tanaka E., Takizawa T., Moribe K., Tomono K., Tashiro T., Kohno S. Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice. Antimicrob. Agents Chemother. 42:1998;40-44.
14. Pons V., Greenspan D., Lozada N.F., McPhail L., Gallant J.E., Tunkel A., Johnson C.C., McCarty J., Panzer H., Levenstein M., Barranco A., Green S. Oropharyugeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin. Infect. Dis. 24:1997;1204-12047.
15. Schafer K.M., Blechschmidt J., Korting H.C. Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk. Mycoses. 39:1996;329-339.
16. Sinclair A.J., Rossof A.H., Coltmam C.A. Recognition and successful management in pulmonary aspergillosis in leukemia. Cancer. 42:1978;2019-2024.
17. Than K.M., Naing K.S., Min M. Otomycosis in Burma, and its treatment. Am. J. Trop. Med. Hyg. 29:1980;620-623.
18. Van Etten E.W.M., Otte-Lambillion M., Van Vianen W., Ten Kate M.T., Bakker-Woudenberg I.A.J.M. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-deoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J. Antimicrob. Chemother. 35:1995;509-519.
19. Wallace T.L., Paetznick V., Cossum P.A., Lopez-Berestein G., Rex J.H., Anaissie E. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob. Agents Chemother. 41:1997;2238-2243.